Bleeding And Thrombosis

Question 1

Humoral mediators in plasma

Answer 1

Epinephrine
Thrombin

Question 2

Mediators released from activated platelets

Answer 2

adenosine diphosphate, serotonin

Question 3

and vessel wall
extracellular matrix constituents that come in contact with adherent
platelets

Answer 3

Collagen, vWF

Question 4

most
abundant receptor on the platelet surface.

Answer 4

Gp) IIb/IIIa (αIIbβ3

Question 5

We now know that coagulation is normally initiated through
tissue factor (TF) exposure and activation through

Answer 5

the classic extrinsic
pathway but with critically important amplification through elements
of the classic intrinsic pathway,

Question 6

TF is constitutively expressed on the surfaces
of

Answer 6

subendothelial cellular components of the vessel wall, such as
smooth muscle cells and fibroblasts.

Question 7

pivotal protease of the
coagulation system.

Answer 7

Thrombin

Question 8

multifunctional
enzyme that converts soluble plasma fibrinogen to an insoluble fibrin matrix

Answer 8

Thrombin

Question 9

covalently cross-links
and thereby stabilizes the fibrin clot.

Answer 9

Factor 13a

Question 10

acts as an anticoagulant by cleaving and inactivating activated factors
V and VIII.

Answer 10

Activated protein C, accelerated by a cofactor, protein S,

Question 11

cleaves the N-terminal lysine residues
of fibrin, which aid in localization of plasmin activity

Answer 11

thrombin-activatable fibrinolysis inhibitor (TAFI

Question 12

primary inhibitor
of tPA and uPA in plasma.

Answer 12

plasminogen activator inhibitors (PAI-1)

Question 13

main inhibitor of plasmin in human plasma, inactivating any
nonfibrin clot–associated plasmin.

Answer 13

α2-antiplasmin

Question 14

inhibit platelet binding, secretion, and
aggregation.

Answer 14

antithrombotic
effects. They produce prostacyclin, nitric
oxide, and ectoADPase/CD39,

Question 15

activate
fibrinolytic mechanisms through the pro-
duction of tissue plasminogen activator,
urokinase, plasminogen activator inhibi-
tors, and annexin-2.

Answer 15

anticoagulant factors including hepa-
ran proteoglycans, TF pathway inhibitor,
and thrombomodulin.

Question 16

neutralizes
thrombin and other activated coagulation factors by forming a com-
plex between the active site of the enzyme and its reactive center

Answer 16

Antithrombin

Question 17

hallmark of moderate and severe factor VIII and
IX deficiency and, in rare circumstances, of other clotting factor
deficiencies

Answer 17

Spontaneous
hemarthroses